Search Records

The purpose of this Notice of Intent to Amend is to notify that, as a result of consultation, Health Canada will switch certain uses of Polymyxin B to prescription status for veterinary use by adding it to the Veterinary Prescription Drug List (PDL).

The purpose of this Notice of Amendment is to announce the revised listing for Adrenocortical hormones to allow the nonprescription use of triamcinolone acetonide for the conditions listed below. Only the Human part of the PDL has been revised.

The updated screening criteria for Abbreviated New Drug Submissions (ANDS) and their supplements (SANDS) will help assess the completeness of the drug submission and identify significant deficiencies prior to the review process.

The Guidance Document: Fees for the Review of Drug Submissions and Applications has been updated. The Document Change Log has been revised to reflect the changes and other minor revisions.

Health Promotion and Chronic Disease Prevention in Canada: Research, Policy and Practice (the HPCDP Journal) is the monthly, online scientific journal of the Health Promotion and Chronic Disease Prevention Branch of the Public Health Agency of Canada. The journal publishes articles on disease...

Health Promotion and Chronic Disease Prevention in Canada: Research, Policy and Practice (the HPCDP Journal) is the monthly, online scientific journal of the Health Promotion and Chronic Disease Prevention Branch of the Public Health Agency of Canada. The journal publishes articles on disease...

Classification of a therapeutic product determines whether it is regulated as a drug [that is (i.e.) pharmaceutical, biologic, natural health product] or a medical device. The purpose of this notice is to communicate Health Canada's current decision that non-medicated eyewashes should be...

This Notice serves as a revision to the Release of Electronic Specifications for Clinical Trial Applications and Amendments filed in accordance with Guidance Document for Clinical Trail Sponsors: Clinical Trial Applications.

The purpose of this notice is to clarify Health Canada’s interpretation and expectations for all matrix-based stability experiments [that is (i.e.) Long term, Freeze-thaw and Bench top] conducted during bioanalytical method validation.

IO No. 2 supports Canada’s continued focus on dealing with the significant risk that COVID-19 continues to pose to the health and safety of Canadians.